More MS news articles for December 2000

NICE to Commission Further Research on MS Drugs

Press Release

NICE 2000/ 052

Issued: 22 December 2000

NICE is extending the timeline for its appraisal of two drugs ; the beta interferons and glatiramer acetate - used in the treatment of multiple sclerosis, to enable further research to be undertaken on their cost effectiveness.

NICE Chief Executive Andrew Dillon said today;During our appraisal we have considered evidence that included economic models supplied by manufacturers and independent researchers, including data not previously submitted. The models are used to inform our judgement on the cost effectiveness of these drugs.

We have looked carefully at these models and whilst it’s clear that considerable effort has been put into their development, detailed examination has raised a number of issues that the Institute’s Appraisal Committee, using the information available, has been unable to resolve. The evidence relating to the cost effectiveness of these medicines is critically important in this appraisal. The Institute has therefore decided to commission further economic modelling on the beta interferons and glatiramer acetate. The process of specifying, commissioning and evaluating this new research will be transparent. The results will be published in full and consultees in the appraisal will have the opportunity to comment on it. ;


Notes for Editors